Hightide Therapeutics Inc. (2511)

Overview

HighTide Therapeutics, Inc., serving as an investment holding entity, is actively involved in the pioneering, exploration, and realization of innovative treatments aimed at addressing unmet medical necessities within the spheres of metabolic and digestive disorders. Established in 2011 and setting its base in Shenzhen, China, HighTide is committed to pushing the boundaries of medical science, particularly in the discovery and development of multi-functional therapies. The company’s ambition is to breach the gaps in current treatment methodologies for various metabolic and digestive diseases, marking a significant stride towards enhancing patient care and outcomes.

Products and Services

• HTD1801

A forefront candidate in HighTide’s arsenal, HTD1801, is recognized as a gut-liver anti-inflammatory metabolic modulator. This pioneering therapeutic agent specifically targets metabolic dysfunction-associated steatohepatitis (NASH), as well as other critical conditions such as type 2 diabetes mellitus, severe hypertriglyceridemia, primary sclerosing cholangitis, and primary biliary cholangitis. By addressing these ailments, HTD1801 stands at the cusp of revolutionizing treatment approaches for a myriad of metabolic disorders.

• HTD4010

Distinguished as a polypeptide drug, HTD4010 embarks on the mission to alleviate the effects of alcoholic hepatitis, a severe manifestation of alcohol-related liver disease. This product underscores HighTide’s commitment to expanding its therapeutic offerings beyond metabolic syndromes, directing attention towards conditions induced by lifestyle choices with significant health repercussions.

• HTD1804

With a distinct focus on combating obesity, HTD1804 represents another facet of HighTide’s expansive approach towards addressing metabolic diseases. Obesity, a global epidemic, serves as a foundation for numerous health complications, and HTD1804’s development is a testament to the company's dedication to mitigating these widespread health concerns.

• HTD1805

This multifunctional small molecule drug ventures into the realm of metabolic diseases, further solidifying HighTide’s role in confronting various health challenges within this domain. HTD1805 embodies the company’s overarching strategy to innovate and offer substantive advancements in the treatment of complex metabolic disorders.

• HTD2802

Delving into the treatment of inflammatory bowel disease (IBD), HTD2802 signifies a critical extension of HighTide’s therapeutic focus. As a condition that severely impacts the quality of life, the development of HTD2802 reflects the company’s versatile approach towards finding solutions for diseases with significant unmet needs.